This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Stocks in Motion

Shares of Sonus Pharmaceuticals (SNUS) were among the best-performing health-related stocks Tuesday, rising 12% after the company signed a licensing deal with Schering AG , which also agreed to acquire about 15% of Sonus.

The deal gives Schering an exclusive license to Sonus' Tocosol paclitaxel anti-cancer product. As part of the deal, Schering will pay Sonus an upfront fee of $20 million and milestone payments of up to $132 million. "The collaboration with Sonus Pharmaceuticals strategically complements our innovative and extensive internal pipeline of systemic and targeted cancer therapies and reinforces our strong commitment to oncology," Schering said in a statement.

As for the equity investment, Schering bought 3.9 million shares $4.02 apiece, resulting in proceeds of about $15.7 million. Schering also acquired five-year warrants to buy 975,000 shares at an exercise price of $4.42 a share. Shares of Sonus recently traded up 47 cents to $4.53.

Pharmaceutical Product Development (PPDI) rose 11% after the company posted third-quarter results that topped expectations. The drug developer earned $38.4 million, or 66 cents a share, on sales of $273.3 million. Excluding items, the company would have earned 70 cents a share. Analysts polled by Thomson First Call were expecting earnings of 66 cents a share on sales of $246.7 million. A year earlier, the company earned $25 million, or 44 cents a share, on sales of $215.8 million. Shares were trading up $6.21 to $62.46.

Shares of AngioDynamics (ANGO) rose 10% after the company signed a distribution agreement with Bioniche Pharma Group and lifted its 2006 earnings and sales guidance ahead of analysts' expectations. The distribution agreement allows AngioDynamics to exclusively market and distribute Bioniche's Sotradecol injection to radiologists and surgeons in the U.S. Sotradecol, which treats varicose veins, is the only FDA-approved sodium tetradecyl sulfate injection in the U.S.

AngioDynamics now expects 2006 earnings, excluding items, of $7.1 million on sales of at least $76 million. Previously, the company said that it would earn $6.1 million on sales of at least $72 million. Analysts had been expecting earnings of $6.4 million, or 50 cents a share, on sales of $73.9 million. Shares were trading up $1.88 to $21.59.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ANGO $17.08 -0.12%
BMY $65.16 -0.97%
NVAX $8.23 -4.08%
AAPL $132.65 1.82%
FB $81.91 0.47%

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs